A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: GSK4527363
DRUG: Placebo matching GSK4527363
DRUG: Belimumab

Sponsor

GlaxoSmithKline